Amendment to NDA[removed], S-029

First Page		Document Content
Pharmacology Clinical research Epoxides Pfizer Tiotropium bromide Chronic obstructive pulmonary disease Acute exacerbation of chronic obstructive pulmonary disease Placebo Respimat Medicine Health Pulmonology		Amendment to NDA[removed], S-029 Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 2,59 MB Share Document on Facebook

	Microsoft WordSpiriva final redline new IFU.docx DocID: 1rn7z - View Document
	COPD Care Map for Primary Care Patient Name: ______________________________________ DOB: ________________ Year of diagnosis:___________ Co-morbid conditions:______________________________________________________________ DocID: 1qO6l - View Document
	Spiriva® Powder for Inhalation (in Capsule) Tiotropium bromide Consumer Medicine Information DocID: 1fwRM - View Document
	BMJ 2011;342:d2970 doi: bmj.d2970 Page 1 of 2 Editorials DocID: 1aKAn - View Document
	KEY ASPECTS 2014 Andreas Barner, Wolfgang Baiker, Allan Hillgrove, Joachim Hasenmaier, Hubertus von Baumbach (from left to right), the Board of Managing Directors KEY ASPECTS 2014 DocID: 1atQi - View Document